Related Experiment Video
Updated: Apr 29, 2026

Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
Contemporary Concise Review 2024: Chronic Obstructive Pulmonary Disease.
Sarita Thawanaphong1,2,3, Parameswaran Nair1,2
1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.
Non-smoking COPD, prevalent in low-income countries, presents unique challenges. Early detection and targeted therapies like Dupilumab show promise, alongside crucial smoking cessation strategies and comorbidity management for better patient outcomes.
Area of Science:
- Pulmonology and Environmental Health
- Pharmacology and Therapeutics
Background:
- Non-smoking COPD is a significant health issue in low- and middle-income countries (LMICs), particularly affecting women, with biomass fuel exposure and air pollution as key risk factors.
- The eosinophilic endotype of COPD is a distinct biological profile, differing from asthma.
- Early detection of COPD can be enhanced through methods like PRISm, FEV1/FVC Z-scores, and quantitative CT imaging.
Purpose of the Study:
- To review current understanding and management strategies for non-smoking COPD.
- To explore novel therapeutic approaches and diagnostic tools for COPD.
- To emphasize the importance of integrated care, including smoking cessation and comorbidity management.
Main Methods:
- Literature review and synthesis of recent research findings on COPD pathophysiology, diagnosis, and treatment.
- Analysis of clinical trial data for targeted therapies like Dupilumab.
- Discussion of pharmacotherapy options for smoking cessation and management of related conditions.
Main Results:
- Dupilumab demonstrated efficacy in reducing exacerbations and improving lung function in COPD patients with elevated blood eosinophil counts (≥300 cells/μL).
- Biomarkers and imaging techniques offer improved early COPD detection.
- Pharmacotherapies such as cytisine and varenicline are effective for smoking cessation, while e-cigarettes raise safety concerns.
- Addressing mood disorders, dysfunctional breathing, and comorbidities (cardiovascular risk, obesity, sleep-disordered breathing) improves COPD management.
Conclusions:
- Targeted therapies and advanced diagnostic methods are advancing COPD care, especially for non-smoking populations.
- Smoking cessation remains a cornerstone of COPD management, with various pharmacotherapy options available.
- Holistic patient care, encompassing mental health and comorbidity management, is essential for improving quality of life in COPD patients.
More Related Videos
Related Concept Videos
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease I: Introduction
Chronic Obstructive Pulmonary Disease IV: Clinical Manifestations

